RF Lung Ablation Associated With Deaths, FDA Says
This article was originally published in The Gray Sheet
A Dec. 11 FDA health notice links several patient deaths to radiofrequency ablation of lung tumors and notes that the uses were off-label
You may also be interested in...
Survival rates following lung tumor treatment with RITA Medical Systems' StarBurst radiofrequency (RF) ablation device should be assessed at one year, FDA's General & Plastic Surgery Devices Panel recommends
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.